DLBCL

Enzastaurin and a Novel Biomarker Spark Optimism for All Risk Levels of DLBCL

August 09, 2020

In an interview with Targeted Oncology, Grzegorz S. Nowakowski, MD, discussed the promise of the enzastaurin in the diffuse large B-cell lymphoma treatment landscape and the ongoing phase 3 ENGINE study.

R-CHOP Alone Should Be New Standard in Early-Stage DLBCL, Researchers Say

August 08, 2020

Four cycles of R-CHOP alone should be the new standard approach to limited-stage disease for the majority of patients with diffuse large B-cell lymphoma. That’s the conclusion of a new study that used positron emission tomography–directed treatment approaches to assess the outcomes and toxicity associated with the current standard of care.

Early Rituximab Intensification Generates No Differences in Outcomes as Treatment of DLBCL

August 04, 2020

Early rituximab intensification during treatment with R-CHOP demonstrated no difference in outcomes as treatment of patients with diffuse large B-cell lymphoma.

Salvage Blinatumomab Therapy Generates Durable Responses in Relapsed/Refractory DLBCL

August 03, 2020

Blinatumomab as salvage therapy for patients with relapsed/refractory diffuse large B-cell lymphoma may induce durable complete responses and a survival benefit, according to a pooled analysis of 3 clinical trials.

FDA Approves Tafasitamab/Lenalidomide for R/R DLBCL

August 01, 2020

The FDA has approved tafasitamab-cxix in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specific, including DLBCL arising from low-grade lymphoma, and patients who are not eligible for autologous stem cell transplant.

Selinexor Introduces a New Mechanism of Action to Treat Relapsed or Refractory DLBCL

June 22, 2020

In an interview with Targeted Oncology, Michael Schuster, MD, discussed the findings in the phase 2 SADAL study and the importance of the FDA approval of selinexor for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

FDA Approves Selinexor for R/R Diffuse Large B-Cell Lymphoma

June 22, 2020

Selinexor is now the only single-agent, oral therapy approved for the treatment of patients with R/R DLBCL, and the only nuclear export inhibitor approved by the FDA for use in 2 hematologic malignancies, multiple myeloma and DLBCL.

Tafasitamab Plus Lenalidomide Demonstrates Long-Term Efficacy in R/R DLBCL

June 15, 2020

“These results, complimented with a favorable safety profile, indicate the utility of this novel immunological combination as a potential treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma."

Better Outcomes Observed With CAR T-Cell Therapy in Younger Patients With R/R DLBCL

June 06, 2020

Chimeric antigen receptor T-cell therapy lead to poor overall survival outcomes it patients who were 75 years or older with relapsed/refractory diffuse large B-cell lymphoma compared with patients aged 70 to 74 years, but progression-free survival was comparable between the 2 groups.

Targeting CD19 in Diffuse Large B-Cell Lymphoma

May 07, 2020

Experts in the management of diffuse large B-cell lymphoma (DLBCL) discuss the use of novel CD19-antibody mono- and combination therapies to treat relapsed/refractory subpopulations.